The estimated Net Worth of Cornelius P. Iii Mc Carthy is at least $1.86 Milhão dollars as of 30 June 2024. Mr. Carthy owns over 62 units of Medpace Inc stock worth over $1,727,385 and over the last 6 years he sold MEDP stock worth over $0. In addition, he makes $135,104 as Independent Director at Medpace Inc.
Cornelius has made over 7 trades of the Medpace Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently he exercised 62 units of MEDP stock worth $20,743 on 30 June 2024.
The largest trade he's ever made was exercising 4,710 units of Medpace Inc stock on 8 February 2024 worth over $269,271. On average, Cornelius trades about 323 units every 29 days since 2018. As of 30 June 2024 he still owns at least 5,163 units of Medpace Inc stock.
You can see the complete history of Mr. Carthy stock trades at the bottom of the page.
Cornelius P. McCarthy III serves as Independent Director of the Company. Mr. McCarthy has served as the Managing Director and CEO of Fairmount Partners since 2003 and focuses primarily on healthcare and pharmaceutical outsourced services. Prior to founding Fairmount Partners, Mr. McCarthy was Vice President, Managing Director and Head of US Investment Banking at PMG/Investec from 1997 to 2003. Prior to 1997, Mr. McCarthy held a number of legal and investment banking roles. Mr. McCarthy is currently a Director of Atlantic Research Services, LLC and NMS Laboratories, Inc. Additionally, Mr. McCarthy was a Director of Cambridge Biomedical, Inc. from December 2016 until its sale in November 2019, and from 2006 to 2013 he was a Director of predecessor entities of the Company. Mr. McCarthy received his undergraduate degree from the University of Virginia where he was an Echols Scholar and his JD from Villanova Law School. Mr. McCarthy was chosen as a director because of his significant investment and financial experience, his experience in the CRO industry and his experience serving on boards.
As the Independent Director of Medpace Inc, the total compensation of Cornelius McCarthy at Medpace Inc is $135,104. There are 11 executives at Medpace Inc getting paid more, with August Troendle having the highest compensation of $7,712,840.
Cornelius McCarthy is 60, he's been the Independent Director of Medpace Inc since 2018. There are 5 older and 9 younger executives at Medpace Inc. The oldest executive at Medpace Holdings Inc is Fred Davenport, 68, who is the Lead Independent Director.
Cornelius's mailing address filed with the SEC is C/O MEDPACE HOLDINGS, INC., 5375 MEDPACE WAY, CINCINNATI, OH, 45227.
Over the last 8 years, insiders at Medpace Inc have traded over $3,140,136,825 worth of Medpace Inc stock and bought 2,899,276 units worth $330,034,155 . The most active insiders traders include Limited Partnership Medpace..., August J. Troendle, eInvestors, Llc Medpace. On average, Medpace Inc executives and independent directors trade stock every 9 days with the average trade being worth of $40,224,347. The most recent stock trade was executed by Robert O. Kraft on 22 August 2024, trading 8,127 units of MEDP stock currently worth $346,373.
a therapeutically focused leader in research-based drug development, medpace builds strong strategic partnerships with select sponsors to advance the most efficient and cost-effective path to drug approval. as a full service, global clinical research organization (cro), medpace sees itself as a steward of your drug, leveraging its extensive medical and regulatory expertise to deliver additional input, strategy, and efficiencies to each and every phase of the clinical trial. from custom solutions addressing the needs of small and midsize biotechnology companies to full-service offerings for global pharmaceutical companies, medpace has the breadth, depth, and flexibility to deliver a superior result, specific to your needs, on six continents.
Medpace Inc executives and other stock owners filed with the SEC include: